WallStreetZenWallStreetZen

NASDAQ: LXEO
Lexeo Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LXEO

Based on 7 analysts offering 12 month price targets for Lexeo Therapeutics Inc

Min Forecast
$10.00+18.76%
Avg Forecast
$17.86+112.08%
Max Forecast
$30.00+256.29%

Should I buy or sell LXEO stock?

Based on 7 analysts offering ratings for Lexeo Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 42.86%
Buy
4 analysts 57.14%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LXEO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LXEO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their LXEO stock forecasts and price targets.

LXEO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-05
lockedlocked$00.00+00.00%2025-10-21
lockedlocked$00.00+00.00%2025-10-15
lockedlocked$00.00+00.00%2025-10-07
lockedlocked$00.00+00.00%2025-07-31
JP Morgan
Top 17%
84
Strong BuyMaintains$10.00+21.95%2025-05-30
HC Wainwright & Co.
Bottom 4%
4
BuyMaintains$15.00+82.93%2025-05-16

1 of 1

Forecast return on equity

Is LXEO forecast to generate an efficient return?

Company
-61.57%
Industry
247.01%
Market
230.21%
LXEO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LXEO forecast to generate an efficient return on assets?

Company
-48.33%
Industry
98.7%
LXEO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LXEO earnings per share forecast

What is LXEO's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$2.56
Avg 2 year Forecast
-$2.04
Avg 3 year Forecast
-$2.24

LXEO revenue forecast

What is LXEO's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$19.4M

LXEO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LXEO$8.20$17.86+117.77%Strong Buy
VSTM$8.16$15.67+92.00%Strong Buy
ADCT$4.00$7.50+87.50%Strong Buy
CGEM$7.31$26.00+255.68%Strong Buy
BCYC$6.17$18.00+191.73%Buy
View Top Biotech Stocks

Lexeo Therapeutics Stock Forecast FAQ

Is Lexeo Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: LXEO) stock is to Strong Buy LXEO stock.

Out of 7 analysts, 3 (42.86%) are recommending LXEO as a Strong Buy, 4 (57.14%) are recommending LXEO as a Buy, 0 (0%) are recommending LXEO as a Hold, 0 (0%) are recommending LXEO as a Sell, and 0 (0%) are recommending LXEO as a Strong Sell.

If you're new to stock investing, here's how to buy Lexeo Therapeutics stock.

What is LXEO's earnings growth forecast for 2025-2027?

(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.

Lexeo Therapeutics's earnings in 2025 is -$114,172,000.On average, 11 Wall Street analysts forecast LXEO's earnings for 2025 to be -$138,253,908, with the lowest LXEO earnings forecast at -$174,639,926, and the highest LXEO earnings forecast at -$112,835,537. On average, 10 Wall Street analysts forecast LXEO's earnings for 2026 to be -$110,232,678, with the lowest LXEO earnings forecast at -$158,763,569, and the highest LXEO earnings forecast at -$63,505,428.

In 2027, LXEO is forecast to generate -$120,735,914 in earnings, with the lowest earnings forecast at -$159,821,993 and the highest earnings forecast at -$47,062,058.

What is LXEO's revenue growth forecast for 2025-2027?

(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.

Lexeo Therapeutics's revenue in 2025 is $0.On average, 9 Wall Street analysts forecast LXEO's revenue for 2025 to be $0, with the lowest LXEO revenue forecast at $0, and the highest LXEO revenue forecast at $0. On average, 8 Wall Street analysts forecast LXEO's revenue for 2026 to be $0, with the lowest LXEO revenue forecast at $0, and the highest LXEO revenue forecast at $0.

In 2027, LXEO is forecast to generate $1,046,543,527 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,231,972,658.

What is LXEO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LXEO) forecast ROA is -48.33%, which is lower than the forecast US Biotechnology industry average of 109.29%.

What is LXEO's Price Target?

According to 7 Wall Street analysts that have issued a 1 year LXEO price target, the average LXEO price target is $17.86, with the highest LXEO stock price forecast at $30.00 and the lowest LXEO stock price forecast at $10.00.

On average, Wall Street analysts predict that Lexeo Therapeutics's share price could reach $17.86 by Nov 5, 2026. The average Lexeo Therapeutics stock price prediction forecasts a potential upside of 117.77% from the current LXEO share price of $8.20.

What is LXEO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LXEO) Lexeo Therapeutics's current Earnings Per Share (EPS) is -$3.26. On average, analysts forecast that LXEO's EPS will be -$2.56 for 2025, with the lowest EPS forecast at -$3.23, and the highest EPS forecast at -$2.09. On average, analysts forecast that LXEO's EPS will be -$2.04 for 2026, with the lowest EPS forecast at -$2.94, and the highest EPS forecast at -$1.18. In 2027, LXEO's EPS is forecast to hit -$2.24 (min: -$2.96, max: -$0.87).

What is LXEO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LXEO) forecast ROE is -61.57%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.